Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma.

Literature DB >> 24351754

Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma.

Viviana P Lutzky¹, Pauline Crooks, Leanne Morrison, Natasha Stevens, Joanne E Davis, Monika Corban, David Hall, Benedict Panizza, William B Coman, Scott Coman, Denis J Moss.

Abstract

Epstein-Barr virus (EBV) is associated with nasopharyngeal carcinoma (NPC). We assess the safety and tolerability of adoptive transfer of autologous cytotoxic T lymphocytes (CTLs) specific for the EBV latent membrane protein (LMP) in a patient with recurrent NPC. After infusion, the majority of pulmonary lesions were no longer evident, although the primary tumor did not regress.

Entities: Disease Species

Mesh：

Substances：

Year: 2013 PMID： 24351754 PMCID： PMC3910937 DOI： 10.1128/CVI.00121-13

Source DB: PubMed Journal: Clin Vaccine Immunol ISSN： 1556-679X

18 in total

1. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.

Authors: A L Chapman; A B Rickinson; W A Thomas; R F Jarrett; J Crocker; S P Lee
Journal: Cancer Res Date: 2001-08-15 Impact factor: 12.701

2. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies.

Authors: K I Lei; L Y Chan; W Y Chan; P J Johnson; Y M Lo
Journal: Br J Haematol Date: 2000-10 Impact factor: 6.998

3. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.

Authors: Patrizia Comoli; Paolo Pedrazzoli; Rita Maccario; Sabrina Basso; Ornella Carminati; Massimo Labirio; Roberta Schiavo; Simona Secondino; Chiara Frasson; Cesare Perotti; Mauro Moroni; Franco Locatelli; Salvatore Siena
Journal: J Clin Oncol Date: 2005-10-03 Impact factor: 44.544

4. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

Authors: R Khanna; S Bell; M Sherritt; A Galbraith; S R Burrows; L Rafter; B Clarke; R Slaughter; M C Falk; J Douglass; T Williams; S L Elliott; D J Moss
Journal: Proc Natl Acad Sci U S A Date: 1999-08-31 Impact factor: 11.205

5. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.

Authors: Martina A Sherritt; Mandvi Bharadwaj; Jacqueline M Burrows; Leanne E Morrison; Suzanne L Elliott; Joanne E Davis; Laurie M Kear; Richard E Slaughter; Scott C Bell; Andrew J Galbraith; Rajiv Khanna; Denis J Moss
Journal: Transplantation Date: 2003-05-15 Impact factor: 4.939

Review 6. Epstein-Barr virus in tumours.

Authors: I Anagnostopoulos; M Hummel
Journal: Histopathology Date: 1996-10 Impact factor: 5.087

7. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.

Authors: S P Lee; R J Tierney; W A Thomas; J M Brooks; A B Rickinson
Journal: J Immunol Date: 1997-04-01 Impact factor: 5.422

8. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.

Authors: C M Rooney; C A Smith; C Y Ng; S Loftin; C Li; R A Krance; M K Brenner; H E Heslop
Journal: Lancet Date: 1995-01-07 Impact factor: 79.321

9. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.

Authors: Karin C M Straathof; Catherine M Bollard; Uday Popat; M Helen Huls; Teresita Lopez; M Craig Morriss; Mary V Gresik; Adrian P Gee; Heidi V Russell; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal: Blood Date: 2004-11-12 Impact factor: 22.113

Review 10. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

Authors: Andrew D Hislop; Graham S Taylor; Delphine Sauce; Alan B Rickinson
Journal: Annu Rev Immunol Date: 2007 Impact factor: 28.527

16 in total

1. Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.

Authors: Sharon D Stoker; Zlata Novalić; Maarten A Wildeman; Alwin D R Huitema; Sandra A W M Verkuijlen; Hedy Juwana; Astrid E Greijer; I Bing Tan; Jaap M Middeldorp; Jan Paul de Boer
Journal: J Cancer Res Clin Oncol Date: 2015-04-29 Impact factor: 4.553

Review 2. Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine.

Authors: Corey Smith; Rajiv Khanna
Journal: Immunol Cell Biol Date: 2017-01-10 Impact factor: 5.126

3. Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo.

Authors: Mei-Chun Lin; Yong-Chong Lin; Syue-Ting Chen; Tai-Horng Young; Pei-Jen Lou
Journal: BMC Cancer Date: 2017-01-05 Impact factor: 4.430

4. EBV based cancer prevention and therapy in nasopharyngeal carcinoma.

Authors: Ya Cao
Journal: NPJ Precis Oncol Date: 2017-05-15

Review 5. Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment.

Authors: Sin-Yeang Teow; Hooi-Yeen Yap; Suat-Cheng Peh
Journal: J Pathog Date: 2017-12-31

Review 6. Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma.

Authors: Chang-Yu Chen; Yung-Song Lin; Chien-Ho Chen; Yin-Ju Chen
Journal: J Biomed Sci Date: 2018-03-29 Impact factor: 8.410

7. Clinical Effect of Adjuvant Cytokine-Induced Killer Cells Immunotherapy in Patients with Stage II-IVB Nasopharyngeal Carcinoma after Chemoradiotherapy: A propensity score analysis.

Authors: Jing-Jing Zhao; Shu Zhou; Chang-Long Chen; Hong-Xia Zhang; Zi-Qi Zhou; Zheng-Rong Wu; Yuan Liu; Qiu-Zhong Pan; Qian Zhu; Yan Tang; Jian-Chuan Xia; De-Sheng Weng
Journal: J Cancer Date: 2018-10-20 Impact factor: 4.207